UNLIKE MANY OTHER medical conditions, an abdominal aortic aneurysm (AAA) is generally asymptomatic and detected incidentally through clinical examination, imaging investigations for other conditions, or targeted screening studies. Unfortunately, intervention at the time of symptomatic presentation (namely AAA rupture) carries high mortality and morbidity. Therefore, the primary focus of treatment is early identification in asymptomatic patients and treatment at clinically recommended thresholds.
The aim of this article is to review current information on population and targeted screening for AAA, and the role of surveillance imaging in the lead-up to and after surgical repair in greater depth than previous summaries. It is assumed that readers are familiar with the basic concepts described in previous papers on aortic and non-aortic aneurysms. 1, 2 
Population screening for abdominal aortic aneurysm
There are no official AAA screening programs in Australia, despite population screening programs in the UK and Sweden, where there is an 80% uptake, 3 and numerous other European countries. Australian Medicare rules prohibit reimbursement for population screening studies; however, targeted screening of individual patients, on the basis of age, smoking history and family history of AAA, can be requested by any medical practitioner and is funded through the Medicare Benefits Schedule in Australia as part of clinically justified investigations.
On the basis of evidence showing substantial benefit, the US Preventive Services Task Force (USPSTF) recommends one-time ultrasonography screening for men aged 65-75 years who have ever smoked. 4 Selective screening for men in the same age group but with no smoking history still offers moderate public health benefit. However, no clear benefit exists for screening of women, even those with a smoking history. Longterm assessment of the Multicentre Aneurysm Screening Study (MASS) randomised trial 5 demonstrated an approximate halving of mortality rates in men aged 65-74 years with screening. There were also health economic benefits, with a reported £7600 gain over a 10-year period. Outcomes from the UK NHS 6 and Swedish 7 Nationwide AAA screening programs support these findings.
Interestingly, the Western Australian screening trial 8 is the only randomised trial so far to report no benefit from population screening. It is postulated that the lack of benefit is due to a high rate of incidental imaging or high levels of detection and treatment of AAA through routine clinical care in the Western Australian population, along with the challenges of delivery to a geographically remote population.
Most recently, in the Danish Viborg Vascular (VIVA) screening trial, a randomised controlled study of patients with AAA, peripheral arterial disease and hypertension, screening of 50,156 participants did not show any reduction in AAA-related deaths but did show an absolute risk reduction in all-cause mortality of 0.006 (admittedly, with wide 
Objectives
This article is the second of two that will outline current areas of controversy and research in AAA disease in order to support a more detailed understanding of issues in managing patients with this condition, and inform the development of Australasian clinical guidelines and health policy.
Discussion
Screening and surveillance of AAA should be evidence-based and follow clinical guidelines; however, advances in treatment technology and epidemiological data have influenced results. Goals of care and cost-effectiveness should play central parts in screening and surveillance strategies.
confidence intervals [CI] of 0.001, 0.011) with one preventable death for each 169 (89-1811) men invited to participate. 9 The justification for screening programs has been further revisited by the publication of a 2017 meta-analysis 10,11 of all reported trials, which concluded that screening reduces AAA-related deaths (odds ratio [OR] 0.66, 95% CI: 0.47, 0.93, P <0.02). A reduction in overall mortality in the invited men was also shown (hazard ratio [HR] 0.98, 95% CI: 0.96, 0.99, P = 0.003). Identification of men with smaller aneurysms not indicated for intervention (<5 cm) allows for cardiovascular best medical management, improving overall health and optimisation for future aortic intervention. These studies also show that men who do not accept the offer to be screened have a higher mortality rate for AAA-related and unrelated diseases, highlighting the value of healthcare engagement for these patients.
Screening for related aneurysms
There are no accepted recommendations regarding screening for thoracic aortic aneurysm (TAA) in patients with AAA; however, additional family history of AAA, hypertension, obesity, African-American ethnicity and a large AAA on presentation have been suggested as factors to trigger screening for TAA. Traditionally, familial screening has been recommended for primary relatives over the age of 65 years, but recent evidence suggests that this should also be extended to younger relatives in whom there is clinical evidence of a collagen, elastin or connective tissue disorder such as Marfan or Loeys-Dietz syndromes. There are data suggesting that 12.6% of patients treated for an AAA continue to develop a metachronous TAA, 12 while 20-25% of patients with TAA have an associated AAA.
We suggest that all patients with AAA should be screened for TAA at the time of diagnosis, with plain X-ray in two planes or non-contrast computed tomography (CT). We also suggest that patients with a primary presentation of a large AAA should undergo at least echocardiography to exclude aortic root dilatation and bicuspid aortic valve or ascending arch aneurysm, as well as ultrasonography for popliteal artery aneurysm (PAA). Conversely, patients with newly diagnosed with TAA may also benefit from AAA and PAA screening.
Post-detection surveillance regimen
While aortic aneurysm surveillance is generally recommended on the basis of maximal aortic diameter, it is recognised that this is merely a crude surrogate marker for rupture risk (Figure 1 ). Current research explores materials modelling, 13 computational fluid dynamics and finite element analysis in order to predict how aneurysms will grow and the potential location and timing of rupture. 14 Biological markers are also being investigated to determine whether they are viable measures of aneurysm activity for the sake of clinical management. 15 At this time, maximal aortic diameter remains the primary surveillance tool; however, significant nuance exists in the determination of this measurement. For example, in a tortuous aorta a transverse or axial diameter may overstimate the size of the aneurysm. Most specialists will use a maximal outer-to-outer wall diameter perpendicular to the line of flow on CT as the true reference diameter for an aneurysm.
Even this diameter may not be reflective. For example, in a saccular aortic aneurysm, it is debatable whether the diameter of the saccular component or the entire vessel represents the clinically relevant predictor of rupture risk. In general, surgeons will have a lower threshold for treatment of saccular aneurysms.
In general, suggested surveillance intervals have been based on rupture risk and expected growth rates, estimated from the size of the aneurysm. The UK Small Aneurysm Trial (UKSAT) 16 observed expansion rates as follows: The 2010 European Society for Vascular Surgery (ESVS) guidelines 17 were based on modelling data from the UKSAT data. 18 Recently published US Society for Vascular Surgery (SVS) guidelines for AAA surveillance 19 incorporating data from the RESCAN collaborators 20 included cost-effectiveness factors in their recommendations; however, these factors may not be applicable to other jurisdictions or cohorts. No guidelines have been published or endorsed by the Australian and New Zealand Society for Vascular Surgery (ANZSVS) to date. It remains to be seen whether the new surveillance intervals suggested by the SVS will gain traction among vascular surgeons ( Table 1 ). Imaging is commonly performed six weeks after repair, for early evaluation of the operative site and graft, using ultrasonography or CT angiography (CTA) , depending on body habitus. A follow up at 3-5 years is often performed for assessment of thoracoabdominal or aortoiliac aneurysmal progression, anastomotic false aneurysm or polyester graft degeneration, 21 and then intermittently after that at the treating doctor's discretion. Delayed complications after open repair, such as synthetic graft infection, aorto-enteric fistula or anastomotic haemorrhage, are rare but can be disastrous. 22
Postoperative surveillance

Surveillance after endovascular aneurysm repair
The integrity of endovascular aneurysm repair (EVAR) can be compromised by continued aneurysmal expansion, endoleak, migration of stents and component separation. Long-term surveillance consumes resources and may lead to unnecessary re-intervention. With a growing number of patients with EVAR, surveillance alone can consume the imaging resources of a high-volume centre. In this situation, it is desirable to survey patients who are at high risk for complications.
Graft failure after EVAR is not usually due to a single cause. Multiple factors contribute to failure in achieving long-term aneurysmal exclusion. The factors 23 can broadly be categorised into:
• aneurysm anatomy (short neck, angulation, thrombus in neck, tortuous vessels, disease progression)
• device factors (integrity issues, poor design)
• physician factors (suboptimal device selection, implantation technique). With progressive evolution in EVAR experience, techniques and designs, lower long-term failure rates from EVAR are expected.
The early experience of EVAR mandated routine six-monthly CTA; however, although it is a sensitive, reproducible tool, there are issues with contrast nephropathy, cumulative lifetime radiation exposure and resource availability. Duplex ultrasonography (DUS) is a comparable tool 24 but has limitations of operator variation and is difficult to coordinate across centres.
Current strategies have tried to minimise the use of repeated CTA on the basis that early freedom from endoleak predicts freedom from long-term aneurysm-related mortality at five years, 25 and that early CTA indicators of highrisk can be used to guide the strictness of future surveillance. Similarly, early 30-day DUS negative for endoleak or limb stenosis appears predictive of a low re-intervention rate of 2% at three years. 26 Stratification of patients into low risk and high risk in the early perioperative period can be used to select the population that requires strict follow-up with imaging. High-risk factors include unfavourable aneurysm anatomy, recognised suboptimal surgical issues, emergency or ruptured AAA repairs, and early-phase imaging evidence of endoleak or failure of sac shrinkage by 5 mm in 12 months.
Low-risk patients can be surveyed without the need for frequent CT beyond the first 12 months. The risk of further aneurysmal degeneration around the three-year mark deserves imaging in both low-risk and high-risk groups.
Most vascular surgeons will perform CTA at least once in the year after EVAR, interspersed with DUS and plain X-ray. Indicators of possible endoleak are failed residual sac shrinkage on ultrasonography, or evidence of graft or component migration on X-ray or CT. Endoleaks can be detected on DUS, and sensitivity can be assisted with contrast enhancement, 27 but confirmation usually requires delayed-phase CTA or selective angiography.
Surveillance of patients who are too fragile to undergo intervention for secondary repair or re-intervention should be reconsidered on an individual basis, with an emphasis on the patient's quality of life and minimal psychological distress. Essentially, cessation of surveillance should be considered for patients who will not be candidates for open repair or endovascular revision surgery.
Conclusions
Targeted population screening has been welcomed in some countries as there is evidence for a reduction in AAA-related deaths and improvement in cardiovascular outcomes in patients on surveillance, particularly men. We have previously outlined surveillance guidelines in our prior publications to assist surveillance once an AAA has been detected. These recommendations take into account the growth rate of the AAA and rupture risk at a given size.
The risk of graft failure and disease progression necessitates ongoing surveillance following EVAR. Tailored surveillance programs are used to minimise the resources allocated to ongoing surveillance. However, it is accepted that surveillance is paramount for long-lasting success with EVAR ( Figure 2 ).
AAA disease continues to provide fertile ground for ongoing surgical research, and future developments will range from better surgical technique and medical devices, improved detection and counselling, the promise of pharmacotherapy, and 
